Researchers have been excited about Retatrutide , a groundbreaking dual agonist showing promising outcomes in early trials for size reduction . It acts by targeting two pathways : GLP-1 and GIP, that , when engaged , assist control appetite and boost energy expenditure . Preliminary observations indicate considerable weight reduction and potential